Predicting the sites of metastases from lung cancer using molecular biologic markers. (Q48743316)

15 February 2018

title

Predicting the sites of metastases from lung cancer using molecular biologic markers. (English)

1 reference

15 February 2018

author

Michael S. Kinch

6

1 reference

15 February 2018

author name string

D'Amico TA

1

1 reference

15 February 2018

Aloia TA

2

1 reference

15 February 2018

Moore MB

3

1 reference

15 February 2018

Conlon DH

4

1 reference

15 February 2018

Herndon JE 2nd

5

1 reference

15 February 2018

Harpole DH Jr

7

1 reference

15 February 2018

language of work or name

English

0 references

publication date

1 October 2001

1 reference

15 February 2018

The Annals of Thoracic Surgery

published in

1 reference

15 February 2018

volume

72

1 reference

15 February 2018

issue

4

1 reference

15 February 2018

page(s)

1144-1148

1 reference

15 February 2018

Revisions in the International System for Staging Lung Cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Survival in early-stage non-small cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 CM in diameter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Molecular biologic substaging of stage I lung cancer according to gender and histology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Overexpression of the EphA2 tyrosine kinase in prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

The role of E-cadherin-catenin complex: more than an intercellular glue?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

A randomized trial of surgery in the treatment of single metastases to the brain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0003-4975%2801%2902979-4

10.1016/S0003-4975(01)02979-4

7 January 2021

Identifiers

DOI

1 reference

15 February 2018

PubMed ID

11603427

1 reference

15 February 2018